title: Combined MRI and ³¹P-MRS investigations of the ACTA1(H40Y) mouse model of nemaline myopathy show impaired muscle function and altered energy metabolism.
abstract: Nemaline myopathy (NM) is the most common disease entity among non-dystrophic skeletal muscle congenital diseases. Mutations in the skeletal muscle α-actin gene (ACTA1) account for ∼25% of all NM cases and are the most frequent cause of severe forms of NM. So far, the mechanisms underlying muscle weakness in NM patients remain unclear. Additionally, recent Magnetic Resonance Imaging (MRI) studies reported a progressive fatty infiltration of skeletal muscle with a specific muscle involvement in patients with ACTA1 mutations. We investigated strictly noninvasively the gastrocnemius muscle function of a mouse model carrying a mutation in the ACTA1 gene (H40Y). Skeletal muscle anatomy (hindlimb muscles and fat volumes) and energy metabolism were studied using MRI and (31)Phosphorus magnetic resonance spectroscopy. Skeletal muscle contractile performance was investigated while applying a force-frequency protocol (from 1-150 Hz) and a fatigue protocol (80 stimuli at 40 Hz). H40Y mice showed a reduction of both absolute (-40%) and specific (-25%) maximal force production as compared to controls. Interestingly, muscle weakness was associated with an improved resistance to fatigue (+40%) and an increased energy cost. On the contrary, the force frequency relationship was not modified in H40Y mice and the extent of fatty infiltration was minor and not different from the WT group. We concluded that the H40Y mouse model does not reproduce human MRI findings but shows a severe muscle weakness which might be related to an alteration of intrinsic muscular properties. The increased energy cost in H40Y mice might be related to either an impaired mitochondrial function or an alteration at the cross-bridges level. Overall, we provided a unique set of anatomic, metabolic and functional biomarkers that might be relevant for monitoring the progression of NM disease but also for assessing the efficacy of potential therapeutic interventions at a preclinical level.
authors.affiliation: Aix-Marseille Université, Centre National de la Recherche Scientifique (CNRS), Centre de Résonance Magnétique Biologique et Médicale (CRMBM) Unité Mixte de Recherche (UMR), Marseille, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Gineste
authors.forename: Yann
authors.initials: Y
authors.lastname: Le Fur
authors.forename: Christophe
authors.initials: C
authors.lastname: Vilmen
authors.forename: Arnaud
authors.initials: A
authors.lastname: Le Troter
authors.forename: Emilie
authors.initials: E
authors.lastname: Pecchi
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Cozzone
authors.forename: Edna C
authors.initials: EC
authors.lastname: Hardeman
authors.forename: David
authors.initials: D
authors.lastname: Bendahan
authors.forename: Julien
authors.initials: J
authors.lastname: Gondin
mesh_terms: D000199:Actins / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D004734:Energy Metabolism / Q000235:genetics / Q000502:physiology; D005260:Female; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D008817:Mice, Mutant Strains; D018482:Muscle, Skeletal / Q000378:metabolism* / Q000473:pathology*; D017696:Myopathies, Nemaline / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*
chemical_list: D000199:Actins